drugset / Trial / NCT00487305
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the safety and immune activity of three doses of tumor vaccine. In recent years, researchers at the Dana-Farber Cancer Institute have discovered that vaccines made from patient's own cancer cell, that have been engineered in the laboratory to produce a protein called GM-CSF, can be effective in stimulating a powerful immune response specific to that cancer. GM-CSF is a naturally occuring hormone in the body that helps our immune system fight infections and diseases. One of the goals of this study is to determine whether these vaccinations will improve the immune system's ability to recognize and destroy the participant's lymphoma cells.
Timeline
- Start
- 2007-06
- Primary completion
- 2023-07-25
- Completion
- 2023-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells | Vaccine | 100000 cells | Subcutaneous |
| Subject | Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells | Vaccine | 5e+06 cells | Subcutaneous |
| Subject | Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells | Vaccine | 1e+07 cells | Subcutaneous |
| Subject | Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells | Vaccine | 5e+07 cells | Subcutaneous |